THURSDAY, MAY 2, 2019: DAY 1

8:00 – 8:30 REGISTRATION AND BREAKFAST

8:30 – 8:45 INTRODUCTIONS AND WELCOME

8:45 – 10:20 SESSION I: LABORATORY MODELS OF NETS

8:45 – 8:50 SESSION INTRODUCTION
Chair/Panel Moderator
Daniel Chung, MD
Co-Chair, NETRF Board of Scientific Advisors

8:50 – 9:05 MODELING NEUROENDOCRINE NEOPLASMS USING ADULT STEM CELL-DERIVED ORGANOIDS
Talya Dayton, PhD (Hans Clevers Lab)
Hubrecht Institute, The Netherlands

9:05 – 9:20 DEVELOPMENT OF EX-VIVO MODELS OF METASTATIC NEUROENDOCRINE TUMOURS
Raj Srirajaskanthan, PhD
Kings College London, United Kingdom

9:20 – 9:35 DEVELOPMENT OF 3D MODELS FOR NEUROENDOCRINE TUMORS
Charlotte Kuperwasser, PhD
Tufts School of Medicine, Boston MA

9:35 – 9:45 DISSECTING LYSINE METHYLTRANSFERASE SIGNALING IN PANCREATIC NEUROENDOCRINE TUMORS
Pawel Mazur, PhD
University of Texas MD Anderson Cancer Center, Houston TX

9:45 – 10:05 PARTNERING WITH PATIENTS TO CREATE A NEUROENDOCRINE TUMOR DEPENDENCY MAP
Jesse Boehm, PhD
Broad Institute, Cambridge MA

10:05 – 10:20 Q AND A DISCUSSION

10:20 – 11:00 COFFEE BREAK

11:00 – 12:00 SESSION II: IMMUNO-ONCOLOGY AND NETS

11:00 – 11:05 SESSION INTRODUCTION
Chair/Panel Moderator
George Fisher, MD PhD
Co-Chair, NETRF Board of Scientific Advisors
11:05 – 11:20  SINGLE DOMAIN ANTIBODY-DIRECTED CAR T CELLS POTENTLY SUPPRESS NEUROENDOCRINE TUMORS IN PRECLINICAL MODELS
Xianxin Hua, MD PhD
University of Pennsylvania, Philadelphia PA

11:20 – 11:35  SYSTEMATIC EVALUATION OF THE IMMUNE ENVIRONMENT OF NEUROENDOCRINE TUMOURS
Chrissie Thirlwell, MD PhD FRCP (Presenting for Tim Meyer MRCP PhD)
University College London, United Kingdom

11:35 – 11:45  NOVEL ANTIBODY-DRUG CONJUGATE (ADC) FOR PANCREATIC NEUROENDOCRINE TUMOR (PNET) TARGETED THERAPY
Renata Jaskula-Sztul, PhD
The University of Alabama at Birmingham

11:45 – 12:00  Q AND A DISCUSSION

12:00 – 1:30  LUNCH

1:30 – 2:40  SESSION III: DETECTING AND TARGETING NETS

1:30 – 1:35  SESSION INTRODUCTION
Chair/Panel Moderator
Evan Vosburgh, MD
NETRF Board of Scientific Advisors

1:35 – 1:50  A NOVEL APPROACH FOR PET IMAGING OF NEUROENDOCRINE TUMORS
Babak Behnam Azad, PhD
Johns Hopkins School of Medicine, Baltimore MD

1:50 – 2:05  SOMATOSTATIN RECEPTOR LIGANDS CAN BE USED TO IMAGE AND TREAT MURINE PNETS INDUCED BY MEN1-LOSS
Brian Untch, MD
Memorial Sloan Kettering Cancer Center, New York NY

2:05 – 2:15  NETCURE—SHINE NEW LIGHT ON NEUROENDOCRINE TUMOR THERAPY
Martin Gotthardt, MD
Radboud University Nijmegen Medical Centre, The Netherlands

2:15 – 2:25  FUNCTIONALIZED SILICA NANOPARTICLES: DEVELOPMENT OF A COMBINED PET AND TAT THERANOSTIC AGENT FOR NEUROENDOCRINE TUMORS
Tara Mastren, PhD
University of Utah, Salt Lake City UT

2:25 – 2:40  Q AND A DISCUSSION

2:40 – 3:00  COFFEE BREAK
3:00 – 4:40  SESSION IV: ADVANCES IN NET TREATMENT: NUCLEAR MEDICINE

3:00 – 3:05  SESSION INTRODUCTION
Chair/Panel Moderator
Lisa Bodei, MD PhD
NETRF Board of Scientific Advisors

3:05 – 3:20  DEVELOPING NOVEL COMBINATION THERAPIES FOR USE WITH 177LU-OCTREOTATE PRRT IN NETS, FOCUSING ON DNA-REPAIR MECHANISMS
Rodney Hicks, MD
University of Melbourne, Australia

3:20 – 3:35  SIMULTANEOUS AUGER E- AND B¯-PARTICLE THERAPY OF METASTASIZED NET USING 161TB-DOTATOC
Cristina Muller, PD Dr (Roger Schibli Lab)
Paul Scherrer Institut, Switzerland

3:35 – 3:45  EVALUATION OF 225AC-DOTATATE FOR TREATMENT OF LUNG CARCINOID TUMORS
David Morse, PhD
H. Lee Moffitt Cancer Center and Research Institute, Tampa FL

3:45 – 3:55  NOVEL RADIOLIGANDS TO IMPROVE RADIOTHERAPY OF NEUROENDOCRINE TUMORS
Kuo-Shyan Lin, PhD
British Columbia Cancer Agency Branch, Canada

3:55 – 4:20  ADVANCEMENTS IN THERANOSTICS FOR NETS - NEW PEPTIDES, ISOTOPES AND SCANNERS
Richard Baum, MD PhD
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Germany

4:20—4:40  Q AND A DISCUSSION AND DAY ONE DISCUSSION BY SESSION CHAIRS

4:40 – 5:30  RECEPTION

FRIDAY, MAY 3, 2019: DAY 2

8:30 – 9:50  SESSION I: PRE-CLINICAL ADVANCES IN NETS

8:30 – 8:35  SESSION INTRODUCTION
Chair/Panel Moderator
Matthew Meyerson, MD PhD
Dana-Farber Cancer Institute, Boston MA
Friday
8:35 – 8:50  DAXX FUNCTIONS IN DEVELOPMENT, TISSUE HOMEOSTASIS, AND PANCREATIC NEUROENDOCRINE TUMOR SUPPRESSION  
Amanda Wasylishen, PhD (Gigi Lozano Lab)  
University of Texas MD Anderson Cancer Center, Houston TX

8:50 – 9:05  EPIGENETIC REGULATORS OF INTESTINAL ENDOCRINE CELLS AND CARCINOID TUMORS  
Pratik Singh, PhD (Ramesh Shivdasani Lab)  
Dana-Farber Cancer Institute, Boston MA

9:05 – 9:20  NOVEL MECHANISMS OF ACQUIRED EVEROLIMUS RESISTANCE IN PANCREATIC NEUROENDOCRINE TUMORS  
Chester Chamberlain, PhD (Michael German Lab)  
University of California, San Francisco CA

9:20 – 9:50  Q AND A DISCUSSION

9:50 – 10:20  COFFEE BREAK

10:20 – 12:10  SESSION II: CRACKING THE CODE

10:20 – 10:25  SESSION INTRODUCTION  
Chair/Panel Moderator  
Ramesh Shivdasani, MD PhD  
NETRF Board of Scientific Advisors

William R. Sellers, MD  
Broad Institute, Boston MA

10:55 – 11:10  WHAT ARE THE MOLECULAR CAUSES OF SMALL INTESTINAL NEUROENDOCRINE TUMORS  
Matthew Meyerson, MD, PhD  
Dana-Farber Cancer Institute, Boston MA

11:10 – 11:25  THE ROLE OF ATRX/DAXX/H3.3 CHROMATIN REGULATION IN PNETS  
Laura Banaszynski, PhD  
UT Southwestern Medical Center, Dallas TX

11:25 – 11:40  PANCREATIC NEUROENDOCRINE NEOPLASMS: DISSECTING THE MOLECULAR HETEROGENEITY  
Kevin Yang, PhD (Sharon Gorski Lab)  
Genome Sciences Centre, BC Cancer Agency, Canada

11:40 – 11:55  EXPLORING THE ROLE OF SIRT6 IN PNET PROGRESSION  
Lisa Poole, PhD (Sita Kugel Lab)  
Fred Hutchinson Cancer Research Center, Seattle WA
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:55 - 12:10</td>
<td>Q AND A DISCUSSION</td>
<td></td>
</tr>
<tr>
<td>12:10 - 1:15</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1:15 - 3:00</td>
<td>SESSION III: NEW CLINICAL STRATEGIES</td>
<td></td>
</tr>
<tr>
<td>1:15 - 1:20</td>
<td>SESSION INTRODUCTION</td>
<td>Chair/Panel Moderator: Chrissie Thirlwell, MD PhD FRCP, NETRF Board of Scientific Advisors</td>
</tr>
<tr>
<td>1:20 - 1:35</td>
<td>BIOMARKERS OF RESPONSE TO CABOZANTINIB IN PATIENTS WITH NEUROENDOCRINE TUMORS</td>
<td>Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute, Boston MA</td>
</tr>
<tr>
<td>1:35 - 1:50</td>
<td>NEW STRATEGIES TO IMPROVE DRUG DEVELOPMENT IN CARCINOID TUMORS</td>
<td>Emily Bergsland, MD, University of California San Francisco CA</td>
</tr>
<tr>
<td>1:50 - 2:00</td>
<td>PHASE 1 STUDY OF SAFETY AND IMMUNOGENICITY OF SURVIVIN LONG-PEPTIDE VACCINE (SURVAXM) WHEN GIVEN IN COMBINATION WITH SOMATOSTATIN ANALOGUE IN PATIENTS WITH SURVIVIN-POSITIVE METASTATIC NEUROENDOCRINE TUMORS (NETS)</td>
<td>Renuka Iyer, MD, Roswell Park Cancer Center, Buffalo NY</td>
</tr>
<tr>
<td>2:00 - 2:10</td>
<td>NET-SMART THERAPY: DEVELOPING A NEUROENDOCRINE TUMOR-TARGETED CHEMOTHERAPEUTIC</td>
<td>Justin Annes, MD PhD, Stanford University Medical Center, Palo Alto CA</td>
</tr>
<tr>
<td>2:10 - 2:20</td>
<td>Q AND A DISCUSSION</td>
<td></td>
</tr>
<tr>
<td>2:20 - 3:00</td>
<td>PANEL DISCUSSION: KEY TAKE-AWAY POINTS AND PRIORITIES FOR FUTURE RESEARCH</td>
<td>NETRF Scientific Advisors and Moderators</td>
</tr>
<tr>
<td>3:00</td>
<td>ADJOURNMENT</td>
<td></td>
</tr>
</tbody>
</table>